Testing for mutations can influence treatment options available to patients with MPNs and provide a more in-depth understanding into their essential thrombocythemia (ET), polycythemia vera (PV) or myelofibrosis (MF) diagnosis. MPN specialist, Dr. Srdan Verstovsek reviews three key mutations that may impact treatment timing and approaches.
Dr. Srdan Verstovsek is Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome.
Subscribe now to receive the latest news on Myeloproliferative Neoplasm (MPN) treatment and research: powerfulpatients.org/connect
MPN Treatment: Why Testing for Mutations Matters
Теги
Dr. Srdan VerstovsekMD Anderson Cancer CenterMPNMyeloproliferative NeoplasmPolycythemia VeraMyelofibrosisEssential ThrombocythemiaMFPVETphlebotomybloodlettingJakafidriver mutationsomatic mutationbone marrow biopsyfibrosisMPL mutationCalreticulin mutationCALRthrombotic eventthrombosisblood clotbaby aspirinenlarged spleensplenomegalyInterferonJAK inhibitorstem cell transplantanemiaJAK-STAT pathway